Locally Advanced Pancreatic Adenocarcinoma Clinical Trial
Official title:
Ablative Radiation Therapy With High Dose Geometric Boost for Locally Advanced Pancreatic Cancer Following Treatment Response Evaluation of Induction Chemotherapy: a Phase II Clinical Trial
The goal of this clinical trial is to test the effect of high-dose radiation therapy after initial chemotherapy in patients with locally advanced pancreatic cancer. The main question it aims to answer is: • For patients with locally advanced pancreatic cancer that responded to initial chemotherapy (stayed stable or decreased in size), will high-dose RT (radiation therapy) contribute to improving treatment outcomes, enhancing quality of life, or increasing overall survival rates? Participants will: - Undergo a tumor biopsy. - Undergo induction chemotherapy (chemotherapy given before radiation therapy) with modified FOLFIRINOX (FFX) or gemcitabine and nab-paclitaxel (GnP). - If the participants disease remains stable or improves after chemotherapy, they will be treated with high dose radiation therapy (If the participants cancer progresses after chemotherapy, they will be treated by their doctor according to standard of care practices). - Complete quality of life questionnaires. - Donate research blood samples.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05679674 -
Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
|
N/A | |
| Recruiting |
NCT04617821 -
AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer
|
Phase 3 | |
| Completed |
NCT03673137 -
Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04652206 -
Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.
|
Phase 1/Phase 2 | |
| Completed |
NCT02394535 -
Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06399172 -
OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy
|
||
| Withdrawn |
NCT03536182 -
Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT04395469 -
FAZA PET/MRI Pancreas
|
N/A | |
| Active, not recruiting |
NCT01585805 -
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT05607953 -
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
|
Phase 1 | |
| Not yet recruiting |
NCT06381154 -
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03269526 -
BATs Treatment for Pancreatic Cancer, Phase Ib/II
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05524090 -
PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer
|
||
| Completed |
NCT01342224 -
Immunochemoradiotherapy in Patients With Pancreatic Cancer
|
Phase 1 | |
| Completed |
NCT01278368 -
Effect Of Preoperative Chemotherapy On Short-Term Outcome After Pancreatic Resection
|
N/A | |
| Recruiting |
NCT04172532 -
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to Radiation Therapy for Localized Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04423731 -
Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer
|
||
| Not yet recruiting |
NCT06272162 -
Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy
|
N/A | |
| Active, not recruiting |
NCT00669734 -
Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
|
Phase 1 | |
| Recruiting |
NCT04665947 -
First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer
|
Early Phase 1 |